Engflag

Dermogen

Quick links to important sections

Dermogen

Dermogen_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermogen

Dermogen is a specialized synthetic combination drug product, classified as a prescription-only medicine designed for topical use and local application. The formulation's distinctiveness lies in its unique blend, which is clinically recognized for its ability to target two critical components of localized ailments: severe inflammation and bacterial infection.

Quick Facts

Property Description
Active Ingredients Dexamethasone, Gentamicin, Neomycin
Pharmacological Class Corticosteroid and Aminoglycoside combination
Common Type Anti-inflammatory and Anti-infective
Origin Synthetic
Route of Administration Topical

What Type of Medicine is Dermogen?

Dermogen is a multi-ingredient formulation that belongs to the therapeutic class of corticosteroid and aminoglycoside combinations. Its fundamental identity is rooted in its strategic, dual functionality, delivering both potent anti-inflammatory and powerful anti-infective capabilities within a single pharmaceutical entity. The final dosage form is typically manufactured as a sterile solution or a semi-solid ointment, allowing its effects to be concentrated precisely at the localized treatment site (e.g., eye, ear, or skin).

What is Dermogen Composed Of?

Dermogen's active components are the glucocorticoid Dexamethasone and the two aminoglycoside antibiotics, Gentamicin and Neomycin. The combination utilizes their water-soluble salt forms, such as Dexamethasone Sodium Phosphate, Gentamicin Sulphate, and Neomycin Sulfate, for stability. The combined use of a steroid and an antibiotic is a widely accepted practice to address inflammation and concurrent infection.

What is the General Purpose of This Combination Drug?

The general purpose of Dermogen is to provide comprehensive management for localized conditions where a significant inflammatory condition and a susceptible bacterial infection are simultaneously present. This dual-action therapeutic strategy aims to achieve both immediate symptom control and fundamental microbial eradication. The Dexamethasone component provides the essential anti-inflammatory action to quickly reduce discomfort and swelling, while the aminoglycosides deliver a robust bactericidal effect against the source of the infection.

Regulatory References

  1. World Health Organization (WHO)
  2. WHO Model List of Essential Medicines

What side effects are possible with Dermogen?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of the Dexamethasone, Gentamicin, and Neomycin combination (Dermogen) as documented in official government regulatory labels. The potential risks are categorized based on their frequency, the affected organ system, and specific safety considerations tied to the duration of use or patient population.

Officially Documented Adverse Reactions

The most frequent adverse reactions reported are generally local, including transient eye irritation, stinging sensation, pruritus (itching), and ocular hyperaemia (eye redness). Other local reactions documented under the Skin and Subcutaneous Tissue Disorders and Immune System Disorders categories include local hypersensitivity and allergic sensitizations, particularly to the anti-infective components. Many serious systemic and localized effects are classified with a Frequency Not Known due to the topical administration route.

Serious and Duration-Related Safety Patterns

Certain serious adverse reactions are explicitly linked to the duration of exposure to the corticosteroid component. Prolonged use is associated with the risk of developing elevated intraocular pressure (glaucoma), potential optic nerve damage, and posterior subcapsular cataract formation. Systemic effects, though rare with topical application, include adrenal suppression and Cushing’s syndrome, which are risks associated with long-term continuous use and systemic absorption. The label notes the risk of ototoxicity (irreversible hearing loss) and nephrotoxicity from the aminoglycoside components if significant systemic absorption were to occur.

Population-Specific Safety Considerations

Safety constraints are noted for specific populations. Regulatory documents indicate that the risk of corticosteroid-induced ocular hypertension may be greater and occur earlier in children than in adults. The product is generally not recommended during pregnancy due to the teratogenic potential of Dexamethasone demonstrated in animal studies. Caution is also advised regarding the potential for cross-sensitivity between Neomycin and other aminoglycosides.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Dermogen, typically resulting from excessive or prolonged topical application, or use on large or damaged skin areas, can lead to systemic absorption of its active ingredients.

Documented Overdose Manifestations

Over-absorption of the corticosteroid component can lead to documented signs of HPA axis suppression (adrenal suppression), a Cushingoid state, hyperglycemia, and glucosuria. Over-absorption of the aminoglycoside components (Gentamicin, Neomycin) may result in documented ototoxicity (e.g., hearing changes, dizziness) and nephrotoxicity (kidney damage). These severe manifestations can potentially escalate to serious outcomes, including irreversible hearing loss or renal failure. Pediatric patients and individuals with impaired renal function are noted as populations at increased risk of systemic toxicity.

When to Seek Urgent Help

If signs of systemic toxicity or overdose manifestations are observed, the regulatory requirement is the immediate cessation of the product. Urgent medical attention must be sought immediately if regulator-listed signs of toxicity are experienced, such as sudden hearing changes or signs of compromised kidney function. The official procedural instruction for overdose management is limited to symptomatic and supportive treatment, often requiring specialized HPA axis function testing and renal function monitoring to assess the extent of systemic exposure. No specific antidote for this overdose scenario is generally known or documented in the regulatory labeling.

Therapeutic Uses of Dermogen

What Dermogen Treats: Main Uses and Benefits

Dermogen is a combination treatment relevant for localized conditions where the patient experiences both significant inflammation and a concurrent bacterial infection. Its therapeutic focus includes symptomatic support across key therapeutic domains. These combinations may be relevant in clinical settings marked by increased discomfort or tension.

The medicine is commonly used to help with acute symptoms related to infections and inflammatory processes across three main domains: acute otitis externa, bacterial conjunctivitis, and infected inflammatory skin conditions like eczema or dermatitis. It is relevant for managing pronounced symptoms of a flare-up, including intense, often disruptive itching (pruritus), along with swelling, redness, and purulent discharge. This supportive benefit contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Co-Occurring Symptoms
Symptom Category Benefit Provided (Soft)
Severe Inflammation (Redness, Swelling) Contributes to easing the overall symptom load.
Co-occurring Bacterial Symptoms (Discharge) Contributes to easing the overall symptom load linked to the presence of bacteria.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dermogen?

The eligibility for Dermogen is strictly defined by regulatory authorities and is classified into populations for whom use is allowed, restricted, or contraindicated.

Dermogen is contraindicated and must not be used by individuals with a known hypersensitivity or allergy to Dexamethasone, Gentamicin, Neomycin, or any other Aminoglycoside antibiotic. Absolute non-eligibility also applies to patients with active viral diseases (such as herpes simplex) or fungal diseases at the treatment site, or patients diagnosed with Myasthenia Gravis. For ear applications, the medicine is prohibited if a perforated ear drum is known or suspected.

Use is restricted in several populations. It is not established or not recommended for children younger than two years of age, and prolonged use must be avoided in all pediatric patients due to the risk of systemic effects like adrenal suppression. The medicine is not recommended during pregnancy or for prolonged use while breastfeeding. Special caution is required for patients with pre-existing renal impairment or hepatic impairment, as this may increase the systemic risk associated with the aminoglycoside components.

What should I know about interactions with other medicines?

Dermogen Interactions with other medicines and products

The official interaction profile for Dermogen (Dexamethasone, Gentamicin, Neomycin) is structured around two categories of risk documented in regulatory sources that are relevant when the medicine's components are systemically absorbed.

Pharmacodynamic Interaction: Additive Organ Toxicity Risk

The most significant interaction involves a pharmacodynamic risk of additive toxicity from the aminoglycoside components (Gentamicin and Neomycin). Co-administration with other medicines formally documented as nephrotoxic (kidney-damaging) or ototoxic (inner ear-damaging) is cautioned against in regulatory labels. These substances, which include certain Loop Diuretics and Vancomycin, increase the documented risk of organ damage.

Pharmacokinetic Interaction: Metabolic Clearance

The Dexamethasone component is subject to a documented pharmacokinetic interaction involving the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors, such as Ritonavir or Ketoconazole, is officially documented to increase the plasma concentration and exposure of Dexamethasone by reducing its clearance. Conversely, CYP3A4 inducers such as Phenytoin may decrease Dexamethasone exposure.

Population-Specific Interaction Notes

Official prescribing information notes that patients with pre-existing impaired renal function are at a heightened risk of aminoglycoside toxicity (ototoxicity and nephrotoxicity) if systemic absorption occurs, due to the reduced clearance of Gentamicin and Neomycin in this population.

Mechanism of Action

The action of Dermogen is defined by two complementary mechanistic domains: modulation of inflammatory pathways and inhibition of microbial protein synthesis. The Dexamethasone component acts as a high-affinity agonist for the intracellular Glucocorticoid Receptor (GR). This interaction initiates a complex mechanistic cascade involving transrepression of pro-inflammatory transcription factors like NF-κB, and upregulation of anti-inflammatory proteins (e.g., Annexin A1). This modulation suppresses inflammatory pathways and limits the synthesis of mediators like prostaglandins and cytokines, leading to a functional change characterized by decreased local vascular permeability and reduced tissue fluid accumulation.

The antibiotics, Gentamicin and Neomycin, engage a distinct target: the bacterial 30S ribosomal subunit. By binding to this essential structure, they cause a fundamental disruption of microbial protein synthesis through translational misreading. This mechanistic interference leads to the synthesis of non-functional proteins that compromise the bacteria’s cellular integrity, resulting in rapid bacterial cell death. The mechanism provides a targeted action against microbial life. This bactericidal mechanism is constrained, however, as its effectiveness is significantly reduced in anaerobic (low-oxygen) microenvironments.

Dosage and Administration Information

How Dermogen is Used: Administration Guidelines

Dermogen is a specialized combination product (Dexamethasone, Gentamicin, Neomycin) intended for strictly topical ophthalmic application and must never be used for injection. The use instructions establish a precise protocol that governs administration route, dosing frequency, and duration limits.

Administration and Dosage Structure

The frequency of use is determined by the severity of the condition. For the ophthalmic suspension (drops), the dose is one or two drops per application. In severe initial cases, the medicine may be used as frequently as every hour. For milder cases, the frequency is reduced, typically to four to six times daily. The ophthalmic ointment is generally applied as a small ribbon (e.g., a half-inch) three to four times daily. This high-frequency dosing must be tapered (gradually reduced) as the symptoms subside, under the guidance of a prescriber.

Procedural Requirements and Duration Limits

Instructions require the patient to shake the suspension well before each use. To maintain sterility and prevent contamination, care must be taken to avoid touching the dropper or tube tip to the eye or any other surface. The drug is intended for short-term use, with the full prescribed duration typically limited to 7 to 10 days. The prescription order for the drug, including any renewal, is subject to a specific procedural constraint: continuation beyond a limited initial quantity (e.g., 8g of ointment or 20mL of suspension) requires mandatory professional re-evaluation of the patient. Regarding age, the medication is approved for use in pediatric patients aged 2 years and older, with use in younger children determined by the physician.

This structured use protocol ensures that administration adheres strictly to established standards for frequency, dose intensity, and short-term application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dermogen

Evidence for Use in Bacterial Conjunctivitis and Ocular Inflammation

Research was studied for the combination of a corticosteroid (like Dexamethasone) and antibiotics (Gentamicin and Neomycin) within short-term Randomized Controlled Trials (RCTs) and specialized regulatory studies. These trials was evaluated in settings exploring how symptoms related to ocular inflammation—a condition characterized by fluctuating manifestations—change over time. Outcomes monitored included changes in the physical signs of inflammation, functional measures like visual acuity, and whether the presence of bacterial colonies was observed in the study period. Research so far describes that these combination drops was studied for use in acute symptoms associated with infection and inflammation in the eye. The follow-up durations were limited, typically 5 to 10 days, so the long-term effects are not fully established.

Evidence for Use in Acute Otitis Externa (AOE)

The research supporting the use of this combination class for external ear infections was evaluated in short-term RCTs, systematic reviews, and meta-analyses. These studies research examined individuals with acute inflammation and concurrent bacterial infection of the external ear canal. The trials primarily focused on outcomes related to physical discomfort, monitoring the rate at which clinical resolution was observed in the study, the resolution of ear discharge (referred to as a “dry ear”), and the severity of symptoms like ear pain (otalgia) and swelling. Evidence quality varies across studies, and different patterns were observed across studies comparing specific combinations.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known—and what is still uncertain. Key areas where data are still emerging or evidence is limited include: Comparative evidence is lacking for the specific triple-drug combination versus every other topical combination; long-term effects are not fully established; and subgroup findings are uncertain for specific patient populations, particularly very young children or those with complex presentations of the inflammatory conditions.

Key Studies & References

  1. WHO Model List of Essential Medicines
  2. Systematic Reviews and Regulatory Documents on Topical Antibiotic-Corticosteroid Combinations for Otitis Externa

Frequently Asked Questions (FAQ)

Common questions about Dermogen (FAQ)

Q: What happens if I forget to use Dermogen one day?

According to the official product information, if a missed application is remembered, official guidance advises applying the medicine as soon as possible. However, if it is almost time for the next scheduled application, official guidance states that the missed application is to be skipped entirely. This procedural guidance is in place to help prevent using a double amount of medicine at one time.

Q: What should I do if I get Dermogen in my mouth?

Regulatory information indicates that if the drops or ointment have been accidentally ingested (swallowed), fluid should be consumed. As a general safety precaution, the documentation advises contacting a health authority or emergency center for guidance, even if symptoms are absent, to ensure appropriate action is taken.

Q: Do older adults need a different amount of Dermogen?

Official documentation concerning the antibiotic components does not suggest that older adults require a different amount compared to younger adults. Specific studies comparing the use of Gentamicin in the elderly with other age groups have not shown that the medicine is expected to cause different side effects or problems.

Q: Is Dermogen associated with weight changes?

The active ingredients include a corticosteroid, Dexamethasone. Systemic use (administration throughout the body) of this class of medicine is known to cause weight gain. Although systemic absorption is rare with topical application, this pattern is noted in regulatory labels for the corticosteroid component.

Q: Can I use Dermogen on broken skin or an open wound?

Official information notes that the corticosteroid component may be associated with delayed wound healing. Official guidance notes that use on broken skin or wounds may increase the amount of the antibiotic components (Gentamicin/Neomycin) that the body absorbs, which increases the potential for systemic effects.

Q: What is the purpose of the inactive ingredients in Dermogen?

Regulatory documents list inactive ingredients, which are generally included to create the final medicine form, such as an ointment or suspension. These components are essential for maintaining the medicine's stability, ensuring consistency, and allowing it to be applied correctly to the localized site.

Q: What information should I read before starting Dermogen?

Official guidance emphasizes reading the accompanying patient information leaflet or instruction sheet thoroughly before starting the medication. This documentation contains important warnings, proper administration instructions, and information regarding when to seek professional consultation.

Q: Can Dermogen be used on the face or near the eyes?

The ophthalmic dosage form of the medicine is officially indicated for use in the inflammatory conditions affecting the eye itself and surrounding structures, such as the eyelid and conjunctiva. This includes conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

How should Dermogen be stored and disposed of?

Storage and Handling Requirements

Dermogen must be stored according to official regulatory specifications to maintain the quality and stability of its ingredients. The product must not be stored above 25°C and it is prohibited to freeze the medicine. To protect the formulation from degradation, it must be stored in its original container or carton to shield it from light and maintain sterility.

Like all medicines, Dermogen must be stored out of the sight and reach of children.

Storage Restriction Requirement
Temperature Do not store above 25°C. Do not freeze.
Container Keep in original, tightly closed container. Protect from light.
Stability Discard after the printed expiry date.

Disposal Instructions

Any unused or expired Dermogen must be disposed of according to local regulatory requirements for medicinal products. To protect the environment, the medicine must not be thrown away via wastewater systems or household trash unless specifically authorized by local health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dermogen found in:

A-Z Index: